Application of artificial intelligence in the diagnosis and treatment of Kawasaki disease.

World J Clin Cases

Shaanxi Kawasaki Disease Diagnosis and Treatment Center, Shaanxi Provincial People's Hospital, Xi'an 710000, Shaanxi Province, China.

Published: August 2024

This editorial provides commentary on an article titled "Potential and limitations of ChatGPT and generative artificial intelligence (AI) in medical safety education" recently published in the . AI has enormous potential for various applications in the field of Kawasaki disease (KD). One is machine learning (ML) to assist in the diagnosis of KD, and clinical prediction models have been constructed worldwide using ML; the second is using a gene signal calculation toolbox to identify KD, which can be used to monitor key clinical features and laboratory parameters of disease severity; and the third is using deep learning (DL) to assist in cardiac ultrasound detection. The performance of the DL algorithm is similar to that of experienced cardiac experts in detecting coronary artery lesions to promoting the diagnosis of KD. To effectively utilize AI in the diagnosis and treatment process of KD, it is crucial to improve the accuracy of AI decision-making using more medical data, while addressing issues related to patient personal information protection and AI decision-making responsibility. AI progress is expected to provide patients with accurate and effective medical services that will positively impact the diagnosis and treatment of KD in the future.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238697PMC
http://dx.doi.org/10.12998/wjcc.v12.i23.5304DOI Listing

Publication Analysis

Top Keywords

diagnosis treatment
12
artificial intelligence
8
kawasaki disease
8
learning assist
8
diagnosis
5
application artificial
4
intelligence diagnosis
4
treatment kawasaki
4
disease editorial
4
editorial commentary
4

Similar Publications

Background: Traumatic anterior shoulder dislocation is the most common type of joint dislocation, with an incidence of 11 to 29 per 100 000 persons per year. Controversy still surrounds the recommendations for treatment and the available procedures for surgical stabilization.

Methods: This review is based on pertinent publications (2014-2024) that were retrieved by a selective search in the PubMed and Google Scholar databases.

View Article and Find Full Text PDF

Background: An estimated 17% of all couples worldwide are involuntarily childless (infertile). The clinically identifiable causes of infertility can be found in the male or female partner or in both. The molecular pathophysiology of infertility still remains unclear in many cases but is increasingly being revealed by genetic analyses.

View Article and Find Full Text PDF

Background: Kentucky is within the top five leading states for breast mortality nationwide. This study investigates the association between neighborhood socioeconomic disadvantage and breast cancer outcomes, including surgical treatment, radiation therapy, chemotherapy, and survival, and how associations vary by race and ethnicity in Kentucky.

Methods: We conducted a retrospective cohort analysis using data from the Kentucky Cancer Registry (KCR) for breast cancer patients diagnosed between 2010 and 2017, with follow-up through December 31, 2022.

View Article and Find Full Text PDF

Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.

Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.

View Article and Find Full Text PDF

Factors Associated With Semaglutide Initiation Among Adults With Obesity.

JAMA Netw Open

January 2025

Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.

Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.

Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!